Three key opinion leaders will make much-needed advancements in treatment options for Inflammatory Bowel Disease on new advisory panel.
We are innovating to help humanity achieve some of its most inspiring medical advancements in the 21st century. Read about Microba’s progress, partnership news and latest discoveries.
Using the NEW1000 Family Study, researchers will investigate the role of the microbiome in the developmental origins of health and disease.
Microba Life Sciences has united with Illumina, Inc. to advance understanding of the human gut microbiome in human health and disease.
Mark Capone to strengthen diagnostics platform with 35-year career in life sciences and molecular diagnostics.
Microba Life Sciences, is empowering global consumer goods company Unilever to explore links between sleep and the human gut.
Microba’s commitment to developing life-changing therapeutics derived from the gut microbiome will add a valuable voice to MTIG’s mission.
The partnership's first clinical trial will determine if a new treatment can restore beneficial gut microbiome species and improve symptoms.
Bringing Microba’s world-leading metagenomic sequencing and bioinformatics together with Holobiome’s promising microbiome therapeutic pipeline.
Microba have partnered with Europe’s largest pathology provider, SYNLAB, to deliver leading gut microbiome analysis into Europe.